コーパス検索結果 (right1)
通し番号をクリックするとPubMedの該当ページを表示します
1 Baseline characteristics were balanced across treatments with
2 Baseline characteristics were balanced between the 2 groups.
3 Baseline characteristics were balanced between the two arms.
4 Baseline characteristics were balanced between the two groups
5 9 patients enrolled (Ona + Bev, n = 64; Pla + Bev, n = 65),
baseline characteristics were balanced.
6 Baseline characteristics were collected to identify the risk
7 Baseline characteristics were collected to tabulate MAGGIC sc
8 Baseline characteristics were comparable across treatment gro
9 Baseline characteristics were comparable across years.
10 Baseline characteristics were comparable between groups, incl
11 Baseline characteristics were comparable between groups, incl
12 Baseline characteristics were comparable by arm.
13 gan dysfunctions (55% treated pooled vs 25% placebo); other
baseline characteristics were comparable.
14 Baseline characteristics were compared between the 2 groups.
15 CA/Ph(-) increased the risk of transformation or death when
baseline characteristics were considered with a hazard ratio
16 Baseline characteristics were determined from administrative
17 When observational studies that did not control for
baseline characteristics were excluded, catheter-related bloo
18 Baseline characteristics were generally comparable between gr
19 Baseline characteristics were not different between genders.
20 Demographics, clinical characteristics, and imaging
baseline characteristics were presented by descriptive statis
21 e trial has completed accrual and 206 patients with similar
baseline characteristics were randomized 1:1 to the two study
22 Baseline characteristics were similar across cohorts.
23 Baseline characteristics were similar among groups.
24 Baseline characteristics were similar and representative of p
25 Baseline characteristics were similar between 571 interventio
26 Baseline characteristics were similar between all participant
27 Baseline characteristics were similar between FIX-HF-5C and F
28 Baseline characteristics were similar between groups.
29 In the ILLUMENATE Pivotal Study,
baseline characteristics were similar between groups: 50% had
30 Baseline characteristics were similar between the 2 groups wh
31 Baseline characteristics were similar between the groups rega
32 Baseline characteristics were similar between the haloperidol
33 Baseline characteristics were similar between treatment arms.
34 Baseline characteristics were similar except for mean donor a
35 Baseline characteristics were similar in both groups.
36 Baseline characteristics were similar in both zoledronic acid
37 Baseline characteristics were similar in the early (n = 49) a
38 Baseline characteristics were similar in the intervention (n
39 Baseline characteristics were similar in the intervention (n
40 Baseline characteristics were similar in the patients treated
41 Baseline characteristics were similar in the two cohorts: NBI
42 Baseline characteristics were similar in the two groups; the
43 Baseline characteristics were similar, except more men (56% v
44 Between-group
baseline characteristics were similar.
45 Baseline characteristics were well balanced among sub-cohorts
46 Results
Baseline characteristics were well balanced among the arms.
47 Baseline characteristics were well balanced between study gro
48 Patient demographic and
baseline characteristics were well balanced between the 2 tre
49 Despite variation in indications for GPIs,
baseline characteristics were well balanced between the cangr
50 ghting to create DES- and BMS-treated groups whose observed
baseline characteristics were well-balanced.